From Wikipedia, the free encyclopedia
Chemical compound
Evocalcet (trade name Orkedia) is a drug for the treatment of
hyperparathyroidism.
[1] It acts as a
calcium-sensing receptor
agonist.
[2]
In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on
dialysis.
[3]
References
-
^ Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018).
"A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4): e0195316.
Bibcode:
2018PLoSO..1395316K.
doi:
10.1371/journal.pone.0195316.
PMC
5882164.
PMID
29614098.
-
^ Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018).
"Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060.
doi:
10.1016/j.bmcl.2018.04.055.
PMID
29724589.
-
^
"Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.
|
---|
Parathyroid hormone and analogues | |
---|
Anti-parathyroid hormone agents | Calcitonin derivatives | |
---|
Calcimimetics | |
---|
Vitamin D analogues | |
---|
|
---|